Australia: A Prime Destination for Clinical Trials and Medical Investment Amid Global Healthcare Innovation

From the development of cardiac pacemakers and penicillin to the invention of cochlear implants and the cervical cancer vaccine, and further to the discovery of Helicobacter pylori, Australian scientists have left an indelible mark on the history of human medicine, making significant medical contributions.

Despite having a population of only 25 million, Australia has produced eight Nobel laureates in Physiology or Medicine and cultivated more than 16,000 professionals in biomedical engineering. Australia’s relentless pursuit of high-quality medical services and technology has kept its scientific research in the medical field at the forefront of the world.

Australia’s healthcare system is widely recognized as one of the best in the world. In a 2017 ranking of healthcare systems across developed countries worldwide by the U.S. think tank Commonwealth Fund, Australia ranked second.

Australia’s myriad inherent advantages have propelled it to become one of the world’s premier investment destinations. This article examines why Australia is an ideal destination for international healthcare investors, analyzing its overall medical technological capabilities, healthcare ecosystem, regulatory and review mechanisms, and research and translational capacities.

Australia is a hotspot for international clinical trial activities.

Australia offers international collaboration opportunities for global pharmaceutical R&D institutions to conduct Phase I to IV clinical trials, as well as to develop and manufacture targets, and is regarded as one of the most ideal locations for conducting clinical trials. The competitive advantages of conducting clinical trials in Australia are primarily reflected in three aspects: high research quality, rapid execution, and low costs.

First, clinical trial data from Australia are recognized by major global regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and can be used to support international submissions and regulatory approvals. Clinical trial data generated in Australia may qualify for an IND exemption by the FDA.

Second, Australia’s clinical trial regulation is fast and pragmatic, with straightforward and clear regulatory processes. After submitting a clinical trial application to an Australian Human Research Ethics Committee (HREC), the review cycle typically takes only 4 to 6 weeks. Clinical trial activities can commence once the review is approved.

Additionally, the Australian government has introduced R&D tax incentives, providing eligible companies with a cash tax offset of up to 43.5% on qualifying R&D expenditures. During Phase I clinical trials, clinical trial costs in Australia are 28% lower than those in the United States before tax incentives, and 60% lower after applying the tax incentives.

In 2019, Australia initiated 1,880 clinical trials, with a particularly notable increase in early-phase trials (Phase I and Phase II), and total clinical trial expenditures reached AUD 1.4 billion. Following the outbreak of the COVID-19 pandemic, the Australian government remained committed to investing in and encouraging the development of medical technology, biotechnology, and pharmaceuticals, including research and development, clinical trials, innovation, and manufacturing. Due to Australia’s relatively effective management of the pandemic, clinical trials initiated in the country were able to continue their regulatory submissions even during the pandemic period.

In terms of industrial clusters, Australia has developed numerous leading medical and health industrial parks, such as the Adelaide BioMed City, the Melbourne Biomedical Precinct, and the Gold Coast Health and Knowledge Precinct.

Aerial View of Adelaide BioMed City. Image source: official website https://adelaidebiomedcity.com/

Adelaide BioMed City brings together the South Australian Health and Medical Research Institute (SAHMRI), the Australian Bragg Centre (which houses Australia’s only proton therapy center), three public universities (the University of Adelaide, the University of South Australia, and Flinders University), and numerous industry organizations. Currently, more than 100 biotechnology companies are established in the precinct, specializing in biologics, genetic diagnostics, stem cell research, molecular crop breeding and genetic cultivation, and enhancing livestock productivity.

The Gold Coast boasts extensive health and medical infrastructure, anchored by the Gold Coast Health & Knowledge Precinct—an international, modern medical industry hub. This precinct is home to Gold Coast Private Hospital, Gold Coast University Hospital, Griffith University, and tens of thousands of specialized healthcare and technology professionals. In collaboration with the precinct, Griffith University focuses on research in cutting-edge medical fields, including biomechanics, vaccine development, injury rehabilitation model design, robotic surgical techniques, prevention and treatment of neurosurgical diseases, breast cancer prevention and therapy, ergonomic orthopedic robotic arms, advanced joint replacement technologies, neonatal microenvironment incubators, and pediatric diseases.

The Melbourne Biomedical Precinct enjoys an international reputation for its excellence in research, breakthrough medical discoveries, and research and development, attracting distinguished scientists and investors. The precinct is home to more than 40 biomedical organizations, ranking among the world’s leaders in multiple fields, including infectious diseases, immune disorders, neuroscience, and cancer. It has achieved numerous innovative scientific outcomes, such as in vitro fertilization (IVF) treatment, colony-stimulating factors, critical vaccines (including those for Hendra virus, cervical cancer, and rotavirus), bionic ears, and wearable biosensors.

New South Wales boasts Australia’s largest healthcare system. Located within the state, the Westmead Health and Innovation District provides specialized medical services to over 10% of New South Wales’ population as well as to patients from across Australia. At its core lies the Westmead Health Precinct, which encompasses more than 400,000 square meters of medical development projects. It is Australia’s largest and leading integrated precinct combining healthcare, education, research, and training, housing four major hospitals, four leading medical research institutions, New South Wales’ largest research-intensive pathology service system, and two university campuses. Key focus areas include medtech, pharmaceuticals, the biotechnology industry chain centered on viral vector production facilities, digital health enabled by networked e-health solutions, infectious diseases, and genetic research and clinical trials.

Australia’s medical device and diagnostics industry is a global leader in numerous niche products, such as 3D-customized titanium implants, non-invasive blood glucose monitoring systems, continuous positive airway pressure (CPAP) devices for preventing sleep apnea, extended-wear day-and-night contact lenses, melanoma detection devices, transdermal insulin delivery systems, and diagnostic technologies for sleep disorders, neurophysiology, and cardiovascular diseases.

Image source: Austrade

This stems from Australia’s robust regulatory framework, stringent intellectual property protection system, sustained and substantial investment in research and development, effective mechanisms that support collaborative innovation, and strong domestic and international market demand.

To respond to the COVID-19 pandemic, the Therapeutic Goods Administration (TGA) of Australia prioritized and expedited the approval of medical devices capable of preventing and treating COVID-19, such as in vitro diagnostics (IVDs). In the second half of 2021, the TGA received 654 new notifications for the initiation of clinical trials, representing an increase of approximately 11.8% compared to the same period in 2020 (585 notifications). During the 2020–2021 financial year (July 1, 2020, to June 30, 2021), a total of 6,300 medical device products were approved.

Australia’s domestic environment is highly conducive to the research, development, and commercialization of medical devices, enabling the minimization of product development and time-to-market cycles. Against this backdrop, Australia’s medical device industry has experienced rapid growth, establishing the country as a significant global producer and exporter of medical devices.

As the world’s 15th-largest healthcare market and the fourth-largest in the Asia-Pacific region, Australia boasts a medical device industry ranked among the top 20 globally, with robust market demand. According to Fitch Solutions, the Australian medical device market is projected to achieve a compound annual growth rate (CAGR) of 4.8% from 2019 to 2024, reaching a value of AUD 9 billion by 2024. Key growth areas include medical consumables, diagnostic imaging, dentistry, orthopedics and prosthetics, and patient support products.

Image source: Austrade

Australia’s advantages in the healthcare industry stem from its robust and flexible healthcare system and regulatory framework, a well-developed health ecosystem, an attractive investment environment, and strong policy support.

First, Australia boasts the world’s most comprehensive public healthcare system, Medicare. Australian citizens and permanent residents who hold a Medicare card are entitled to free medical services at any public healthcare institution nationwide.

Leveraging the advantages of its public healthcare system, Australia has established a nationwide electronic medical record system. Nearly 23 million Australians have electronic health records, with over 90% of pharmacies and general practitioners registered and integrated with bed availability data from 94% of public hospitals, positioning Australia as a leader in healthcare information transmission and electronic medical record creation.

Australia’s nationwide healthcare information coordination efforts have also expanded various systems and solutions to encompass areas such as mobile computing platforms for data analytics, clinical analysis of patient data, telehealth services and mHealth development, and management system solutions. To address rising costs, growing demand for personalized care, and an aging population, Australia is implementing digital health solutions to establish a sustainable healthcare system.

In terms of medical regulation, the Therapeutic Goods Administration (TGA), an agency under the Australian Department of Health, safeguards and enhances the health of Australians by providing effective and timely regulation of therapeutic goods—including medicines, medical devices, gene technologies, and blood products. It promotes industry development and product innovation, ensuring that Australia’s medical products and technologies maintain a prominent international standing.

Secondly, Australia’s globally top-tier medical schools, medical research institutes, health and medical precincts, and innovation centers constitute a highly advantageous health ecosystem, creating a superior environment for enhancing the country’s innovation and R&D capabilities and accelerating the translation of scientific research outcomes.

Of particular importance, Australia has introduced a series of supporting policies and preferential measures to attract foreign investment.

From 2019 to 2020, the Australian government announced a A$20 billion Medical Research Future Fund initiative, the largest of its kind globally. Australia’s Research and Development Tax Incentive program provides tax offsets and reimbursements of up to 43.5% of R&D expenditures to both domestic and foreign investors, encouraging biotechnology companies to increase their R&D investment.

Furthermore, to promote the translation of scientific research outcomes, the Australian Government has established the Biomedical Translation Fund (BTF) to assist individuals and institutions with biomedical discoveries in developing biopharmaceuticals, thereby facilitating the commercialization of research findings and effectively ensuring the sustainable and healthy development of Australia’s biopharmaceutical industry.

A well-developed healthcare system, advanced research capabilities, and a favorable business environment have also attracted an increasing number of Chinese investors.

Historical data show that in September 2015, Biostime International Holdings Limited acquired an 83% stake in Swisse Wellness Pty Ltd, the manufacturer of the well-known Australian health supplement brand Swisse, for AUD 1.67 billion; in May 2017, Humanwell Healthcare and CITIC Capital announced a joint acquisition of Ansell’s global sexual wellness business for USD 600 million; in July 2017, Hengkang Medical Group acquired PPR Diagnostic Imaging, a chain of diagnostic imaging centers, for AUD 337 million; and in July 2018, CDH Investments and Grand Pharma jointly acquired the Australian medical device company Sirtex for AUD 1.9 billion, among other transactions.

Healthcare assets have become a significant component of many Chinese investors’ portfolios in Australia. According to a research report by KPMG, the healthcare sector was the largest destination for Chinese investment in Australia in 2018, accounting for 41.7% of China’s total investment in the country. The report predicts that Chinese companies will expand their investments in Australia’s healthcare sector into a broader range of subsectors.

Australia has been actively strengthening exchanges and cooperation with China, forming a sound pattern of all-around, multi-level, wide-ranging, and comprehensive collaboration.

In 2017, Australia’s Cochlear Limited established a cochlear implant manufacturing base in Chengdu, Sichuan Province, marking its first overseas production and R&D facility. As the earliest-founded company with the largest global market share in the cochlear implant industry, Cochlear has been developing its presence in the Chinese market for over two decades. China has now become one of Cochlear’s top three markets and its fastest-growing market.

At the end of 2019, the first ICON Cancer Care radiotherapy center was inaugurated in Jiang County, Shanxi Province. ICON is Australia’s largest integrated oncology healthcare group and the first Australian company to provide cancer care services in China. To date, the ICON Group has established five cancer radiotherapy centers in Jiang County (Shanxi), Chongqing, Laoshan District (Qingdao), Sanmenxia (Henan), and Dandong (Liaoning). By providing technical support to local medical institutions through radiation treatment planning, medical physics support, and specialized clinical training, ICON delivers radiotherapy services to patients.

Uscom and Foxconn Technology Group will integrate their respective strengths in specialized R&D and intelligent manufacturing to collaborate on mass production and quality control, developing more innovative medical devices in the cardiovascular and respiratory fields to meet the growing clinical demand for non-invasive monitoring. Uscom’s flagship product, the Uscom Non-Invasive Hemodynamic Monitor, has undergone over two decades of clinical validation, with more than 600 publications worldwide, and has received support from multiple Chinese funding programs, including the National Natural Science Foundation of China, the National Key R&D Program, and the National Clinical Key Special Project.

As Australia continues to prioritize and upgrade its medical technology sector, a growing number of Australian companies are expanding into international markets, bringing with them increased investment and collaboration opportunities.

To further strengthen exchanges and cooperation between China and Australia in the field of medical devices, Austrade will join forces with eight Australian medical device organizations to exhibit at the 86th China International Medical Equipment Fair (CMEF)!

Meanwhile, the Australian Trade Commission will collaborate with the China Association for Medical Device Industry, the Shenzhen Medical Device Industry Association, and the Shenzhen Kerry Institute of Rehabilitation Medicine to host the “China-Australia Medical Device Cooperation and Exchange Forum” on the morning of November 24, 2022, with a live stream simultaneously.

Event Mini Program Page

QR Code for Event Livestream Registration

China-Australia Medical Device Exchange Group

Recently, AusBiotech hosted a series of medical investment exhibitions, where multiple Australian companies showcased the latest research achievements in Australia’s life sciences sector. Selected case studies are shared below:

Cerecin is a biopharmaceutical company focused on the discovery and development of drugs for the treatment and prevention of brain diseases. Leveraging its expertise in lipid science, the company explores the potential therapeutic benefits of ketone-based medicines. Its lead investigational compound for the treatment of infantile spasms, tricaprillin, has received Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. FDA.

Microba Life Sciences is a precision microbiome genomics company dedicated to improving human health. Leveraging world-leading technology for measuring the human gut microbiome, Microba is driving the development of novel therapies for chronic diseases and providing gut microbiome testing services to researchers, clinicians, and consumers worldwide.

HaemaLogiX is a novel immuno-oncology therapy developer focused on the development and commercialization of monoclonal antibodies for the treatment of multiple myeloma and potentially other hematologic cancers. It has currently identified and characterized two new drug targets, Kappa Myeloma Antigen (KMA) and Lambda Myeloma Antigen (LMA), on the surface of human hematologic cancer and autoimmune cells; these two targets exhibit high specificity for cancer cells found in hematologic malignancies.

Respirion Pharmaceuticals is an early-stage biotechnology company focused on developing novel therapies for respiratory diseases, with its lead product being an inhaled therapy for cystic fibrosis, a life-threatening condition. The company has partnered with the Medical Research Commercialisation Fund, Australia’s largest life sciences investment fund, and the Cystic Fibrosis Foundation to conduct further clinical trials in Australia and the United States.

Carina is a preclinical immunotherapy company dedicated to the research and development of CAR-T cells and other adoptive cell therapies for the treatment of solid tumors. The company is developing broad-spectrum CAR-T therapies that are patient-specific and carry a minimal risk of on-target, off-tumor toxicity. Carina also leverages its proprietary platform to develop technologies that improve access to and infiltration of solid tumors, while enhancing the manufacturing of CAR-T cells.

Telstra Health is a digital health service provider dedicated to delivering digital care solutions to communities, thereby achieving an interconnected and holistic healthcare experience. By collaborating with hospitals, healthcare providers, pharmacies, and aged and disability care sectors, it offers clinical and administrative systems, health data analytics, population health solutions, and health information exchange platforms. These services connect health information, clinicians, and consumers to enhance the quality, safety, and efficiency of healthcare delivery.

Let us look forward to the growing exchanges and cooperation in the healthcare sector between China and Australia, which will provide better disease solutions for patients worldwide!

Source：

[1]https://www.tga.gov.au/resources/publication/publications/annual-performance-statistics-report-july-2019-june-2020

[2]https://www.tga.gov.au/resources/publication/publications/half-yearly-performance-snapshot-july-december-2021

[3]https://adelaidebiomedcity.com/

[4]https://gchkp.com.au/

[5]https://www.melbournebiomed.com/

[6]https://www.westmeadproject.health.nsw.gov.au/precinct/about-westmead-health-precinct#:~:text=Spanning%2075%20hectares%2C%20the%20Westmead%20precinct%20comprises%20more,the%20largest%20research%20intensive%20pathology%20service%20in%20NSW.

[7]https://www.ausbiotech.org/